Lv64
2339 积分 2022-03-04 加入
How should the efficacy of novel treatments be assessed in survival trials?
2天前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
3天前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
3个月前
已完结
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
4个月前
已完结
Common misconceptions of randomized controlled trials in oncology
6个月前
已完结
皖公网安备34019202002308
